Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Liabilities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Total Liabilities for 4 consecutive years, with $96.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 8.49% to $96.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.4 million through Dec 2025, up 8.49% year-over-year, with the annual reading at $96.4 million for FY2025, 8.49% up from the prior year.
  • Total Liabilities hit $96.4 million in Q4 2025 for Taysha Gene Therapies, down from $97.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $244.9 million in Q3 2023 to a low of $83.3 million in Q1 2025.
  • Historically, Total Liabilities has averaged $110.1 million across 4 years, with a median of $98.5 million in 2023.
  • Biggest five-year swings in Total Liabilities: skyrocketed 144.05% in 2023 and later crashed 62.67% in 2024.
  • Year by year, Total Liabilities stood at $125.3 million in 2022, then decreased by 21.97% to $97.8 million in 2023, then decreased by 9.16% to $88.8 million in 2024, then grew by 8.49% to $96.4 million in 2025.
  • Business Quant data shows Total Liabilities for TSHA at $96.4 million in Q4 2025, $97.6 million in Q3 2025, and $84.6 million in Q2 2025.